Dr. Jeffrey L. Cummings (Brain Health) is the lead author of recently published article titled, "evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease." This article is a description of two large global clinical trials of semaglutide for the treatment of Alzheimer's disease.
